<DOC>
	<DOCNO>NCT00150423</DOCNO>
	<brief_summary>To evaluate safety efficacy pregabalin patient painful diabetic peripheral neuropathy .</brief_summary>
	<brief_title>To Evaluate Safety Efficacy Pregabalin Patients With Painful Diabetic Peripheral Neuropathy .</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must meet inclusion criterion precede doubleblind BID study painful diabetic peripheral neuropathy Must receive pregabalin/placebo doubleblind condition minimum 3 week . Patients may participate experience serious adverse event precede doubleblind BID study determine related study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>